NCT01728311View on ClinicalTrials.gov

Open Label Study of BAY1082439 in Patients With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 21, 2012

Primary Completion Date

June 3, 2016

Study Completion Date

February 6, 2017

Conditions
Neoplasms
Interventions
DRUG

BAY1082439

BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.

Trial Locations (5)

10002

Taipei

119228

Singapore

169610

Singapore

03080

Seoul

120-752

Seoul

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01728311 - Open Label Study of BAY1082439 in Patients With Advanced Cancer | Biotech Hunter | Biotech Hunter